Read Pulse
The median company going public in 2024 was 13.5 years old—up from just four years in 1999, according to Forge Global. Andreessen Horowitz puts the current figure at 14 years from founding to IPO. Either way, the message is the same: if you're holding startup equity and waiting for an IPO to turn it into cash, you could be waiting a very long time.
That timeline is what makes the question of when to sell so consequential. Timing your liquidity event isn't just about getting the highest price on a given day. It's about aligning a sale with your financial goals, your tax position, your company's trajectory, and the broader market environment. Get it right and you convert paper wealth into real financial flexibility. Get it wrong—or simply never act—and you risk watching value erode, tax advantages expire, or life pass by while your net worth sits locked inside a single company.
This guide breaks down the factors that determine when to sell startup equity, the triggers that commonly drive a liquidity decision, and how to build a strategy that balances upside potential with the reality that equity you can't spend isn't really wealth.
This is the foundational tension of startup compensation. You might hold shares worth $500,000 on paper. But until those shares are converted into actual dollars through a sale, a tender offer, or a public listing, that number is theoretical. It can go up. It can go down. It can go to zero.
Unlike public stock, which you can sell in seconds on an exchange, private company equity has no guaranteed market. There's no ticker symbol, no daily price, no order book. Selling requires finding a willing buyer, navigating company approval processes, and often waiting weeks or months for a transaction to close. That illiquidity is a feature of private markets—but it also means the window for selling at favorable terms doesn't stay open forever.
Selling too early means potentially leaving significant upside on the table. Selling too late means risking a valuation decline, a missed tax window, or a company-imposed restriction that shuts down the opportunity entirely. The right time is rarely obvious in the moment—which is why understanding the variables that affect timing is so important.
The difference between selling your startup equity in January versus March, or in year three of holding versus year five, can amount to hundreds of thousands of dollars in tax liability. Capital gains treatment, AMT exposure, and QSBS eligibility are all governed by specific holding periods and calendar-year calculations that don't care about your personal convenience.
Valuation timing matters too. Private company valuations can swing dramatically between funding rounds. A company valued at $5 billion in its Series D might be worth $8 billion six months later—or $3 billion if market conditions shift. Secondary market pricing reflects these swings, sometimes with a lag. Selling during a period of strong valuation momentum generally produces better outcomes than selling after a down round or during market uncertainty.
And your options—literally—may have expiration dates. If you leave a company, most stock option agreements give you 90 days to exercise. Miss that window and your vested options can expire worthless regardless of the company's value. The timeline for action may be shorter than you think.
People rarely sell startup equity on a whim. There's usually a catalyst—something that makes the abstract question of "should I sell?" suddenly concrete and urgent. Understanding the most common triggers can help you anticipate your own timing.
An increasing number of late-stage private companies now facilitate secondary sales for employees and early shareholders, often in conjunction with late-stage fundraising. These programs—sometimes structured as tender offers, sometimes as organized secondary windows—give shareholders a company-approved path to partial liquidity.
SpaceX, for example, has run bi-annual tender offers at progressively higher prices, most recently at $421 per share in December 2025. Stripe conducted a tender offer in February 2025 that valued the company at $106.7 billion. These events create defined moments when selling is straightforward, pricing is clear, and company approval is already baked in.
The downside: you don't control the timing. Company-led programs happen on the company's schedule, not yours. If you need liquidity in April but the next tender offer isn't until November, you're either waiting or exploring other channels.
When your company announces a secondary program or tender offer, treat it as a genuine decision point. Evaluate the terms, model the tax impact, and make a deliberate choice rather than letting the window pass by default.
The traditional exit paths—an acquisition or initial public offering—remain the most common sources of broad-based liquidity for startup shareholders. But they come with limited visibility on timing and, often, significant restrictions on when and how much you can actually sell.
The 2026 IPO pipeline is among the deepest in years. According to EquityZen's 2026 outlook, the average age of current IPO candidates is 12 years, with median funding at Series F stage. Companies like SpaceX, Databricks, Canva, Anthropic, and Kraken are all in various stages of IPO preparation. Renaissance Capital counts more than 190 companiesin the current public pipeline.
But "IPO-ready" and "going public tomorrow" are very different things. Market conditions, regulatory hurdles, and internal readiness can delay listings by quarters or even years. And even after an IPO, most employees face a 180-day lockup period during which they can't sell. Recent trends suggest this is evolving—EquityZen noted that 2025 saw an increase in the percentage of shareholder liquidity included in IPO offerings—but lockups remain standard.
If you're counting on an IPO for liquidity, the secondary market may offer a way to access some value in the meantime rather than betting everything on a single, uncertain date.
Sometimes the trigger isn't the company—it's your life. A home purchase, a wedding, the birth of a child, a career change, paying off student loans, or simply the desire to have a meaningful cash cushion after years of deferred compensation.
These aren't lesser reasons to sell. If 70% of your net worth is concentrated in a single illiquid asset, your financial life is effectively hostage to one company's outcome. Selling a portion to fund tangible goals or reduce that concentration is sound financial planning, not a vote of no confidence in your employer.
The key is anticipating these milestones early enough to plan around them. Equity sales take time—often four to eight weeks for a secondary transaction, and potentially longer if company approval or ROFR processing is involved. If you know you'll need capital in six months, start the process now.
There's no formula that tells you the perfect moment to sell startup equity. But there are frameworks that can help you weigh the decision.
Start with the most basic question: what do you need the money for, and when?
If you're optimizing for long-term wealth and have no near-term cash needs, holding may make sense—particularly if your company is on a strong growth trajectory with a credible exit path. The data supports patience in certain cases: Forge Global found that unicorns that went public between 2019 and 2025 showed a median annual appreciation of 65.7% between reaching $1 billion in valuation and their eventual IPO.
But if you're approaching a major life milestone, carrying significant concentrated risk, or simply want to convert some paper gains into real financial flexibility, waiting for the theoretical maximum exit isn't a strategy—it's a gamble. Partial liquidity lets you address immediate needs while preserving exposure to future upside.
Where your company sits in its lifecycle should heavily influence your timing calculus.
Early-stage (Series A-B). Secondary sales at this stage are uncommon and difficult. Buyer interest is limited, pricing is uncertain, and companies are less likely to approve transfers. If you hold equity at this stage, your most realistic liquidity path is continued holding or exercising options early to start tax-advantaged holding period clocks.
Mid-stage (Series C-D). Secondary activity begins to pick up here. Institutional buyers become interested. Pricing becomes more anchored to recent funding rounds. Companies may start exploring structured liquidity programs. This is often the stage where proactive planning has the most impact—particularly for early employees whose equity has appreciated significantly.
Late-stage and pre-IPO (Series E+). This is where the secondary market is most active and liquid. Buyer demand is typically strongest for well-known, late-stage names. Pricing is more transparent. The trade-off: you're potentially selling close to a public exit, which means you need to weigh the certainty of a secondary sale today against the possibility of higher (or lower) value at IPO.
Secondary markets don't exist in a vacuum. Broader conditions—interest rates, public market performance, investor appetite for risk, and the volume of IPO activity—all influence pricing and buyer demand in private markets.
The current environment offers some useful context. SPV activity in the secondary market has surged dramatically, with the number of secondary SPVs up 682% and capital raised up 1,340% compared to 2023 levels, according to a Margin of Signal analysis. That's a signal of strong buyer demand. Meanwhile, the IPO pipeline is deep but unevenly distributed—meaning some companies are closer to a public exit than others, which affects secondary pricing.
The broader lesson: when buyer demand is high and the market is active, sellers generally get better pricing and faster execution. These windows don't last forever.
Tax planning isn't the most exciting part of timing your liquidity event. But it may be the most consequential. The difference between optimal and suboptimal tax timing can easily exceed 20 percentage points of your total proceeds. Tax planning isn't optional if you want to keep as much of the upside as possible.
The federal tax rate on your equity sale depends primarily on how long you've held the shares. Short-term capital gains (assets held one year or less) are taxed at ordinary income rates—up to 37% federally. Long-term capital gains (assets held more than one year) are taxed at preferential rates of 0%, 15%, or 20%, depending on your total taxable income, plus a potential 3.8% net investment income tax.
For startup equity holders, the distinction between short-term and long-term treatment often hinges on the relationship between your exercise date and your sale date. If you exercise options and sell the resulting shares within 12 months, any gain is short-term. Hold for more than 12 months after exercise, and the gain qualifies for long-term treatment. That single calendar distinction can cut your effective tax rate nearly in half.
If you hold shares in a qualifying C-corporation, Section 1202 of the Internal Revenue Code—governing qualified small business stock (QSBS)—may allow you to exclude a significant portion of your capital gains from federal taxes entirely. The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, substantially expanded these benefits.
For QSBS acquired after July 4, 2025, the new rules introduce a tiered exclusion structure based on holding period. Hold for at least three years and you can exclude 50% of eligible gain. Hold for at least four years and the exclusion rises to 75%. Hold for five years or more and you can exclude 100% of eligible gain—up to the greater of $15 million or 10 times your adjusted basis in the stock (increased from the prior $10 million cap).
The corporate eligibility threshold was also expanded: a company's aggregate gross assets can now be up to $75 million (up from $50 million), with inflation adjustments beginning in 2027. This brings a broader range of growth-stage startups within QSBS eligibility.
The timing implication is significant. If you're at three years and seven months of holding QSBS-eligible stock, waiting five more months to cross the four-year threshold could increase your exclusion from 50% to 75%. If you're at four years and eight months, waiting four more months could move you from 75% to 100% exclusion. These are enormous differences in after-tax proceeds, and they should absolutely factor into your sale timing.
Important caveat: QSBS eligibility involves multiple requirements beyond holding period—including the corporation's size, structure, and business activities. Not all startup equity qualifies. A tax advisor familiar with Section 1202 can determine whether your specific shares are eligible and help you optimize timing accordingly.
If you hold incentive stock options, the alternative minimum tax remains one of the biggest timing traps in startup equity. When you exercise ISOs and hold the shares past the end of the calendar year, the spread between your strike price and the current fair market value is included as income in your AMT calculation—potentially creating a six-figure tax liability on gains you haven't actually realized in cash. ISOs work differently than NSOs, and the timing rules matter.
The OBBBA permanently extended higher AMT exemption amounts: $90,100 for single filers and $140,200 for married couples filing jointly in 2026. However, the same law lowered the phase-out thresholds to $500,000 (single) and $1,000,000 (joint) and doubled the phase-out rate from 25% to 50%. The net effect: while the higher exemptions help moderate earners, high-income employees with large ISO exercises may face greater AMT exposure starting in 2026.
The practical advice: if you plan to exercise ISOs, consider doing so early in the calendar year. As tax advisors at the Zajac Group have noted, exercising in January or February gives you the option to sell after one year (meeting the qualifying disposition requirement) and use the sale proceeds to cover your AMT bill before the April tax deadline. Exercise in August or later and you lose that flexibility—you either sell early in a disqualifying disposition or fund the AMT bill from other sources.
This isn't boilerplate advice—it's a genuine recommendation. The interplay between ISO exercise timing, AMT calculations, QSBS holding periods, capital gains treatment, and state tax obligations is complex enough that even financially sophisticated employees regularly make costly mistakes. The cost of a qualified tax advisor or financial planner is almost always a fraction of the savings they generate.
If you're selling a significant portion of your holdings, professional guidance isn't optional. It's part of the cost of doing it right.
Timing your liquidity event shouldn't happen in isolation. It's one piece of a broader financial picture that includes your income, your savings, your debt, your risk tolerance, and your long-term goals.
Concentration risk is one of the most underappreciated dangers in startup compensation. If the majority of your net worth is tied to a single private company, you're exposed to company-specific risk—a product failure, a regulatory change, a market shift, a leadership crisis—that has nothing to do with your own financial planning.
Selling a portion of your equity to diversify into other asset classes—public equities, bonds, real estate, cash reserves—is a time-tested wealth management practice. It doesn't mean you don't believe in your company. It means you recognize that prudent financial management involves not putting all your eggs in one basket, regardless of how promising that basket looks.
The data on private market value creation reinforces why partial diversification makes sense. Andreessen Horowitz found that for the 2014-2019 IPO cohort, over 80% of market capitalization was generated after going public. For more recent IPOs, that ratio has shifted—companies are capturing a higher portion of their value while still private. This means the potential upside from continued holding is real, but it also means you may already be sitting on meaningful gains that could be partially harvested.
Private market liquidity can fund goals that were previously out of reach: a down payment on a home, education planning for children, retirement contributions, charitable giving, or simply building an emergency fund that doesn't depend on a future exit event.
The most effective approach is to define these goals before you sell, then size your liquidity accordingly. Selling $200,000 to fund a specific down payment is a disciplined decision. Selling "some" because the opportunity is available is less strategic and may leave you with regrets in either direction.
This is the core value proposition of partial liquidity: you don't have to choose between selling everything and selling nothing. A calibrated approach—selling 20%, 30%, or 40% of your position while retaining the rest—lets you secure tangible financial gains today while preserving meaningful exposure to your company's future trajectory.
Think of it as rebalancing, not exiting. You're adjusting the allocation of your personal portfolio to reflect your current needs and risk tolerance, not making a binary bet on the company's future.
The secondary market is specifically designed to support this kind of partial-exit approach. Structured transactions through SPVs, platform-facilitated sales, and company-approved programs all allow shareholders to sell a portion of their holdings without requiring a full liquidation.
Augment is a private stock marketplace built to help employees, founders, and early investors navigate the complexity of secondary transactions with clarity and confidence.
The platform offers access to curated secondary opportunities aligned with your company's stage and trading activity. SPV structures allow partial exits without forcing a full sale—so you can access liquidity on your terms while retaining exposure to future upside. Built-in compliance tools handle ROFR processing, lockup verification, and legal documentation, removing much of the friction that historically made secondary sales inaccessible for individual sellers.
Augment connects sellers with a vetted network of accredited and institutional investors actively seeking exposure to top pre-IPO companies. Transparent pricing, informed by real secondary market activity, helps ensure sellers receive fair value. And as a pre-IPO investment platform registered with FINRA, Augment operates within a regulated framework designed to protect both sides of every transaction.
Whether you're an early employee exploring your first partial exit or a founder planning a more significant liquidity event, the platform is designed to make the process structured, compliant, and aligned with your broader financial strategy.
Liquidity timing is choosing when to buy or sell private shares so the transaction lines up with real-world constraints—company permissions, buyer demand, pricing windows, and tax impact. Unlike public markets, private liquidity is episodic. The “best” timing is usually when the company is ready to support transfers, buyers are active, and the seller isn’t forced by a deadline.
IPO delays extend holding periods and push liquidity farther into the future—often by years. That increases the value of interim options like company-led secondaries or structured secondary transactions. It also raises the stakes on timing: if you wait only for an IPO, you may miss earlier windows where pricing is strong and approvals are easier to obtain.
Look at three things: (1) company stage and signals (late-stage demand tends to be stronger; prior tenders/secondaries matter), (2) market conditions (buyer appetite, valuation trends, comparable deals), and (3) deal structure and rights (ROFR, transferability, documentation quality). For buyers, the “right time” is when the risk matches the company’s maturity and the terms offer a believable path to future liquidity.
For sellers, poor timing can mean selling into low demand, taking steeper discounts, or exiting too early and missing upside—especially if the sale is driven by urgency. For buyers, bad timing often shows up as unclear rights, messy documentation, or uncertain liquidity paths that reduce confidence and participation. At the market level, poorly coordinated timing creates friction that can derail deals and discourage repeat activity.
Augment Markets, Inc. is a technology company offering software and data services with securities-related services offered through its wholly-owned but separately managed subsidiary Augment Capital, LLC, Member of FINRA/ SIPC.
Important Disclosures: This material has been prepared for informational purposes only. None of the information provided represents an offer or the solicitation of an offer to buy or sell any security. The information provided does not constitute investment, legal, tax, or accounting advice. You should consult with qualified professionals before making any investment decisions. Investing in private securities involves substantial risk, including the potential loss of principal. Private securities are typically illiquid, have limited pricing transparency, and often require longer holding periods. These investments are available exclusively to qualified accredited investors and offer no guarantee of returns. Additionally, past performance of private securities does not indicate or predict future results.
FOR ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC’s Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
